New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 16, 2013 /PRNewswire/ — Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Tomer Adar, M.D. at the Digestive Diseases Institute, Shaare Zedek Medical Center, Hebrew University of Jerusalem, presented a poster on October 15, 2013 entitled Inhibition of Eotaxin-1 (CCL 11) Ameliorates DSS-Induced Colitis; A Novel Potential Therapeutic Approach for Inflammatory Bowel Disease, at the United European Gastroenterology Week being held in Berlin, Germany.

This study was performed to evaluate the effect of eotaxin-1 (CCL-11) inhibition on BALB/c mice with dextran sodium sulfate (DSS)-induced colitis. The mice were treated with an anti-eotaxin-1 monoclonal antibody or a control antibody. Inhibition of eotaxin-1 resulted in significant amelioration of DSS-induced colitis demonstrated by statistically significant reduction in both disease activity index and body weight loss compared to controls. These results indicate the importance of eotaxin-1 in regulating intestinal mucosal inflammation, and its potential as a future therapeutic target in inflammatory bowel disease (IBD).

Bertilimumab is a fully human monoclonal antibody with high specificity for human eotaxin-1. Bertilimumab was originally developed by Cambridge Antibody Technologies, now part of MedImmune, the Global Research and Development Arm of AstraZeneca. Immune has initiated a double blind placebo controlled Phase II international study, which compares bertilimumab with placebo in 105 patients with moderate to severe ulcerative colitis. Patients are selected based on elevated eotaxin-1 levels from colonic biopsy samples. Topline data from this trial is expected in early 2015.

Eran Goldin, M.D., Chairman of the Digestive Diseases Institute at Shaare Zedek Medical Center in Jerusalem, commented: “Eotaxin-1 is a biomarker of IBD and a potential target for therapeutic intervention. This new selective approach is promising for patients with moderate to severe ulcerative colitis. We look forward to the Phase II clinical data with bertilimumab.


Ulcerative Colitis For Dummies® Now Available Online

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the availability of Ulcerative Colitis For Dummies®, Special Edition. Authored by Boston Medical Center’s Clinical Director in Gastroenterology, Co-Director of the Center for Digestive Disorders, and Professor of Medicine at the Boston University School of Medicine Francis A. Farraye, M.D., M.Sc., this version of the popular Wiley brand reference series features patient-focused information on ulcerative colitis (UC). The free book, available in print and now for download at, is written for patients as an easy-to-use guide that offers basic information including tips for living with UC and answers to commonly asked questions about the condition.

“When it comes to educating patients, it is critical that providers are able to connect in a relatable way to ensure patients have an understanding of their diagnosis,” said Dr. Farraye. “Ulcerative Colitis For Dummies can be used as a conversation tool for patients at all stages to empower better understanding and management of UC.”

Ulcerative colitis is a chronic disease that causes inflammation and sores in the large intestine and rectum. While the condition affects people at any age, most are diagnosed in their 20s and 30s. Life-altering symptoms include diarrhea, frequent, urgent need to have a bowel movement, blood in the stools, abdominal pain, anemia and in some individuals skin, joint and eye symptoms. Without chronic management UC can return at any time.